Company intelligence / Profile preview

Lifex Biolabs

United States

Ownership: Private
Development stage: Other

Overview

Lifex Biolabs is developing innovative small molecule drugs for neurodegenerative and metabolic diseases, with its lead program targeting NR4A2 for Parkinson’s disease currently in preclinical studies

Therapeutic areas: OncologyNeurologyEndocrinology
Modalities: Small moleculeChemical drugs
Industry: Biotech

Drug pipeline

4 assets

LF201

Preclinical

3 more assets in the full pipeline.

Request access →

Partnerships

Macrogen (biomarker selection, strategic investment)

Beyond the preview

Go deeper on Lifex Biolabs.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lifex Biolabs.

Explore the full profile